Neogen Corporation (NEOG)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 2
Do Nothing: technicalScore 2 — price 11.69 is below the SMA20 12.00, SMA50 12.26 and both EMAs with MACD -0.09 negative and ADX 13.87 (no trend), so no qualifying breakout exists; the alternative pullback/oversold limit into the 11.43–11.50 shelf is countertrend (price < SMA50 with MACD < 0) and blocked by the trend-alignment gate.
Company overview
Neogen Corporation is a global company specializing in products for food quality and animal health. It operates through two divisions: Food Safety, which provides diagnostic test kits for contaminants in food and feed, and Animal Safety, offering veterinary instruments, pharmaceuticals, and genomics testing services.
Fundamental
fairNeogen's fundamentals show mixed performance with improving cash flow but high leverage and unresolved litigation issues.
Mixed fundamentals in an improving turnaround: four straight GAAP loss years (FY2023–FY2026) are heavily distorted by a $1.06B non-cash goodwill impairment (FY2025) and a $76.4M one-time divestiture gain (FY2026), while the latest quarter (Q1 FY2027, ended 2026-08-31) shows revenue growth in both segments (+6.5% consolidated), a 47.4% gross margin, a sharply narrowed operating loss, positive operating cash flow and continued debt paydown. Key risks: net debt around 5.7x TTM EBITDA, thin EBIT-based interest coverage, a $1.05B goodwill balance, and unresolved securities-litigation plus product-recall/FDA Warning Letter matters; key protections: $172M cash plus about $200M revolver capacity, covenant compliance, no going-concern issues, and no required maturities before FY2029. A speculative stabilization story — not a clean strong-fundamentals pick, but not a solvency risk either.
Sentiment
fairSentiment is flat, with no immediate catalysts and unresolved regulatory issues affecting the outlook.
Sentiment is flat rather than improving — baseline polarity_score ≈ -0.11 versus scoring ≈ 0.00, both windows measured — with the dominant near-term driver an unresolved, regulator-confirmed FDA warning letter over the Hycoat sterile veterinary product and its follow-on product-liability litigation (bearish, regulator_confirmed) set against a market-rewarded but now trailing Q1 FY2027 revenue beat and raised FY2027 guidance (announced). Red-Flag Screen clean — no severe or moderate flag applied — but the signal set is genuinely mixed with no forward-dated catalyst inside 30 trading days, which holds the setup below the top band.
Technical
weakTechnicals indicate a weak short-term trend with no qualifying breakout, as price remains below key moving averages.
Short-term structure is weak: price 11.69 sits below the SMA20 (12.00), SMA50 (12.26), EMA9 (11.93) and EMA21 (12.03), with MACD -0.09/-0.07/-0.02 negative and rolling over and ADX14 13.87 confirming no directional trend. RSI14 44.87 (below 50) and Williams %R -83.10 show a sold-off but unconfirmed condition — bounce-only, not a trend entry. The long-term frame is intact (price above the SMA200 at 10.50) and the 11.43–11.50 multi-week support shelf is holding, but there is no qualifying momentum breakout (price is in the lower third of the four-week 11.43–12.85 range) and any pullback/oversold limit would be countertrend (price < SMA50 with MACD < 0). technicalScore 2; Do Nothing.
You’re looking at 2026-11-10 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

